Study of A Long Lasting Local Anesthestic for Hand, Wrist or Finger Surgery
Exparel (Bupivacaine Liposome Injectable Suspension) for Distal Upper Extremity Blocks in Orthopedic Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients 18 years or older having hand, wrist, or finger surgery
- ability to understand and provide informed consent
- American Society of Anesthesiologists status I-III
- presence of a responsible adult caregiver for 48-72 hours after surgery
Exclusion Criteria:
- patient refusal or inability to provide informed consent
- true allergy, not sensitivity to local anesthetics, midazolam, fentanyl, hydromorphone, propofol
- pregnancy
- hepatic or renal failure
- evidence of infection at or near the proposed needle insertion site
- any sensorimotor deficit of the upper extremity
- BMI greater than or equal to 35
- uncontrolled or severe pulmonary disease
- anticoagulant use (not aspirin or non-steroidal anti-inflammatories)
- chronic pain patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Bupivacaine supraclavicular block
Under ultrasound guidance, 20-30 mL 0.5% Bupivacaine will be used for the supraclavicular block.
|
20-30mL 0.5% bupivacaine
|
|
Experimental: Exparel forearm block
Under ultrasound guidance, 3-5 milliliters (mL) Exparel will be injected around the 3 nerves of the forearm prior to surgery.
20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
|
20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Onset of Sensorimotor Block
Time Frame: 30 minutes
|
A blinded study staff member will evaluate the subject after the block is performed.
Subjects will be asked to move their hand and will be asked if they can feel a sharp sensation on specific areas of their hand.
Once no movement and no feeling is detected, the block is considered successful and the time will be noted.
|
30 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jose Soberon, MD, Ochsner Health System
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 04262013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.